SLC6A3 and Prader-Willi syndrome: This study constitutes the initial approach to assess the mRNA levels of D3, D5, DAT, 5-HT2A, and SERT in PBMCs from healthy volunteers (HV), drug-naïve PWS, drug-free PWS, and patients treated from 1 to 40 weeks with risperidone.